CL2020002671A1 - Sales de meglumina de tienopirimidinas - Google Patents
Sales de meglumina de tienopirimidinasInfo
- Publication number
- CL2020002671A1 CL2020002671A1 CL2020002671A CL2020002671A CL2020002671A1 CL 2020002671 A1 CL2020002671 A1 CL 2020002671A1 CL 2020002671 A CL2020002671 A CL 2020002671A CL 2020002671 A CL2020002671 A CL 2020002671A CL 2020002671 A1 CL2020002671 A1 CL 2020002671A1
- Authority
- CL
- Chile
- Prior art keywords
- thienopyrimidines
- meglumine salts
- meglumine
- salts
- thienopyrimidine
- Prior art date
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
En la presente se divulgan las sales de meglumina de tienopirimidina según la fórmula (I) utilizada para tratar o prevenir la insuficiencia cardiaca.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658683P | 2018-04-17 | 2018-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002671A1 true CL2020002671A1 (es) | 2021-04-16 |
Family
ID=68161061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002671A CL2020002671A1 (es) | 2018-04-17 | 2020-10-15 | Sales de meglumina de tienopirimidinas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10822346B2 (es) |
| EP (1) | EP3781155A4 (es) |
| JP (1) | JP2021522186A (es) |
| KR (1) | KR20210002541A (es) |
| CN (1) | CN112367989A (es) |
| AU (1) | AU2019255233A1 (es) |
| BR (1) | BR112020021153A2 (es) |
| CA (1) | CA3097384A1 (es) |
| CL (1) | CL2020002671A1 (es) |
| CO (1) | CO2020014069A2 (es) |
| IL (1) | IL278064A (es) |
| MX (1) | MX2020010884A (es) |
| PE (1) | PE20211480A1 (es) |
| PH (1) | PH12020551701A1 (es) |
| SG (1) | SG11202010161UA (es) |
| WO (1) | WO2019204298A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230145313A (ko) * | 2020-11-10 | 2023-10-17 | 유니티 바이오테크놀로지, 인크. | Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377583A (en) | 1981-08-21 | 1983-03-22 | Mead Johnson & Company | N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid |
| WO1989008113A1 (en) * | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| CA2612176C (en) * | 2005-06-14 | 2015-02-17 | Aska Pharmaceutical Co., Ltd. | Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors |
| TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| JP5744017B2 (ja) * | 2010-05-31 | 2015-07-01 | あすか製薬株式会社 | チエノピリミジン誘導体の結晶 |
| AU2014205276B2 (en) * | 2013-01-11 | 2016-10-20 | Novartis Ag | Meglumine salt forms of 2-((1 R,4R)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as DGAT1 inhibitors |
| KR20190049691A (ko) * | 2016-07-07 | 2019-05-09 | 카듀리온 파마슈티칼스, 엘엘씨 | 심부전의 치료 방법 |
-
2019
- 2019-04-16 MX MX2020010884A patent/MX2020010884A/es unknown
- 2019-04-16 BR BR112020021153-2A patent/BR112020021153A2/pt not_active Application Discontinuation
- 2019-04-16 US US16/385,748 patent/US10822346B2/en active Active
- 2019-04-16 EP EP19788035.4A patent/EP3781155A4/en not_active Withdrawn
- 2019-04-16 JP JP2020557319A patent/JP2021522186A/ja not_active Withdrawn
- 2019-04-16 CN CN201980026565.8A patent/CN112367989A/zh active Pending
- 2019-04-16 WO PCT/US2019/027665 patent/WO2019204298A1/en not_active Ceased
- 2019-04-16 KR KR1020207032912A patent/KR20210002541A/ko not_active Withdrawn
- 2019-04-16 SG SG11202010161UA patent/SG11202010161UA/en unknown
- 2019-04-16 PE PE2020001614A patent/PE20211480A1/es unknown
- 2019-04-16 CA CA3097384A patent/CA3097384A1/en active Pending
- 2019-04-16 AU AU2019255233A patent/AU2019255233A1/en not_active Abandoned
-
2020
- 2020-10-14 PH PH12020551701A patent/PH12020551701A1/en unknown
- 2020-10-15 CL CL2020002671A patent/CL2020002671A1/es unknown
- 2020-10-15 IL IL278064A patent/IL278064A/en unknown
- 2020-10-20 US US17/075,148 patent/US20210139499A1/en not_active Abandoned
- 2020-11-11 CO CONC2020/0014069A patent/CO2020014069A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021522186A (ja) | 2021-08-30 |
| WO2019204298A1 (en) | 2019-10-24 |
| AU2019255233A1 (en) | 2020-11-26 |
| CA3097384A1 (en) | 2019-10-24 |
| PH12020551701A1 (en) | 2021-09-06 |
| EP3781155A1 (en) | 2021-02-24 |
| IL278064A (en) | 2020-11-30 |
| MX2020010884A (es) | 2021-02-26 |
| EP3781155A4 (en) | 2021-10-06 |
| US10822346B2 (en) | 2020-11-03 |
| PE20211480A1 (es) | 2021-08-05 |
| CO2020014069A2 (es) | 2021-01-29 |
| SG11202010161UA (en) | 2020-11-27 |
| CN112367989A (zh) | 2021-02-12 |
| US20210139499A1 (en) | 2021-05-13 |
| US20190315765A1 (en) | 2019-10-17 |
| KR20210002541A (ko) | 2021-01-08 |
| BR112020021153A2 (pt) | 2021-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CO2021003036A2 (es) | Compuestos de anillo fusionado | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
| MX2020004538A (es) | Moduladores de la vía de estrés integrada. | |
| MX392673B (es) | Derivados de pirazol como inhibidores de malt1 | |
| MX2020004534A (es) | Moduladores de la vía integrada del estrés. | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CU24603B1 (es) | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios | |
| JOP20170107B1 (ar) | مشتقات سلفوناميد عطرية | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| MX378235B (es) | Métodos para mejora hidráulica de cultivos. | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
| DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
| MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
| EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
| EA201791945A1 (ru) | Пирролидинкарбоксамидопроизводные и способы их получения и их применение | |
| CL2020000376A1 (es) | Compuesto pentacíclico. |